	US 12,161,609 B2
	Composition and method for treating autism spectrum disorder (ASD) symptoms of paranoia with self isolation and/or aggression
John Nagle, Sylmar, CA (US)
Filed by John Nagle, Sylmar, CA (US)
Filed on Jun. 25, 2021, as Appl. No. 17/359,272.
Prior Publication US 2022/0409556 A1, Dec. 29, 2022
Int. Cl. A61K 31/137 (2006.01); A61K 31/165 (2006.01); A61K 31/55 (2006.01); A61P 25/18 (2006.01)

CPC A61K 31/137 (2013.01) [A61K 31/165 (2013.01); A61K 31/55 (2013.01); A61P 25/18 (2018.01)]

18 Claims

1. A method of treating ASD adolescents and adults exhibiting aggression and/or paranoia with social isolation comprising:

administering a three-drug composition comprising:

a pharmacologically effective dose of a serotonin selective reuptake inhibitor;

a pharmacologically effective dose of oxcarbazepine; and

a pharmacologically effective dose of guanfacine; wherein the ASD adolescents and adults have been unsuccessfully treated with risperidone; wherein the serotonin selective reuptake inhibitor is selected from fluoxetine and sertraline.